Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vedanta Biosciences Enrolls First Patient in Phase 3 RESTORATiVE303 Study of VE303
Details : VE303 is a potential first-in-class live biotherapeutic product candidate consisting of a defined bacterial consortium designed for the prevention of recurrent Clostridioides difficile infection.
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 21, 2024
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Brand Name : VE202
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 08, 2023
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : AXA IM Alts
Deal Size : $106.5 million
Deal Type : Financing
Details : The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activitie...
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 25, 2023
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : AXA IM Alts
Deal Size : $106.5 million
Deal Type : Financing
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recur...
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 13, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : affiliates of Magnetar Capital
Deal Size : $68.0 million
Deal Type : Series D Financing
PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing
Details : Proceeds expected to be used primarily to support a Phase 3 trial of Vedanta’s lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD).
Brand Name : VE303
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : affiliates of Magnetar Capital
Deal Size : $68.0 million
Deal Type : Series D Financing
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results further support the benign safety profile of VE202 and identify an optimal dosing regimen. Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021.
Brand Name : VE202
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 29, 2021
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Details : Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
Brand Name : VE202
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 12, 2021
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?